GlycoMimetics/GLYC

$1.85

0.82%
-
1D1W1MYTD1YMAX

About GlycoMimetics

GlycoMimetics, Inc. is a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers, including acute myeloid leukemia (AML) and for inflammatory diseases. It is developing a pipeline of glycomimetics, which are small molecules that mimic the structure of carbohydrates involved in biological processes, to inhibit disease-related functions of carbohydrates, such as the roles they play in inflammation, cancer and infection. Its drug candidates include Uproleselan, GMI-1687, Galectin Antagonists and GMI-1359. It is developing Uproleselan, a specific E-selectin antagonist, to be used in combination with chemotherapy to treat patients with AML, a life-threatening hematologic cancer, and potentially other hematologic cancers. It has designed an antagonist of E-selectin, GMI-1687, that is suitable for subcutaneous administration. GMI-1359 is a drug candidate that simultaneously targets both E-selectin and a chemokine receptor (CXCR4).

Ticker

GLYC

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Harout Semerjian

Employees

35

Headquarters

Rockville, United States

GlycoMimetics Metrics

BasicAdvanced
$116.01M
Market cap
-
P/E ratio
-$0.58
EPS
2.29
Beta
-
Dividend rate
$116.01M
2.29088
$3.53
$1.11
438.4K
6.407
-75.98%
-90.72%
-90.65%
11,601.07
3.017
3.02
-86.67%
34.31%
-90.05%

What the Analysts think about GlycoMimetics

Analyst Ratings

Majority rating from 4 analysts.
Buy

Price Targets

Average projection from 3 analysts.
278.38% upside
High $10.00
Low $3.00
$1.85
Current price
$7.00
Average price target

GlycoMimetics Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$0
-
Net income
$-9M
-2.17%
Profit margin
0%
-

GlycoMimetics Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 8.2%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.17
-$0.13
-$0.14
-$0.14
-
Expected
-$0.17
-$0.18
-$0.14
-$0.15
-$0.15
Surprise
2%
-29.09%
-2.33%
-8.2%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for GlycoMimetics stock?

GlycoMimetics (GLYC) has a market cap of $116.01M as of April 25, 2024.

What is the P/E ratio for GlycoMimetics stock?

The price to earnings (P/E) ratio for GlycoMimetics (GLYC) stock is 0 as of April 25, 2024.

Does GlycoMimetics stock pay dividends?

No, GlycoMimetics (GLYC) stock does not pay dividends to its shareholders as of April 25, 2024.

When is the next GlycoMimetics dividend payment date?

GlycoMimetics (GLYC) stock does not pay dividends to its shareholders.

What is the beta indicator for GlycoMimetics?

GlycoMimetics (GLYC) has a beta rating of 2.29. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the GlycoMimetics stock price target?

The target price for GlycoMimetics (GLYC) stock is $7, which is 278.38% above the current price of $1.85. This is an average based on projections from 3 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell GlycoMimetics stock

Buy or sell GlycoMimetics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing